Henan Cancer Hospital
π¨π³China
- Country
- π¨π³China
- Ownership
- Private
- Established
- 1977-01-01
- Employees
- -
- Market Cap
- -
A Study of Pyrotinib Plus Capecitabine in Patients With Brain Metastases From HER2-positive Metastatic Breast Cancer
Phase 2
Active, not recruiting
- Conditions
- HER2 Positive Metastatic Breast Cancer
- Interventions
- First Posted Date
- 2018-10-01
- Last Posted Date
- 2023-09-25
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 78
- Registration Number
- NCT03691051
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
BCMA-CAR-T in Relapsed/Refractory Multiple Myeloma
Phase 1
- Conditions
- Relapsed/Refractory Myeloma
- Interventions
- Drug: BCMA nanobody CAR-T cells
- First Posted Date
- 2018-09-10
- Last Posted Date
- 2018-09-10
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT03664661
- Locations
- π¨π³
Cancer Hospital Affiliate to Zhengzhou University & Henan Cancer Hospital, Zhengzhou, Henan, China
The Application of 3T MRI in Esophageal Cancer
- Conditions
- Esophageal Cancer TNM StagingMagnetic Resonance ImagingPrognosis
- First Posted Date
- 2018-08-17
- Last Posted Date
- 2020-04-01
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 400
- Registration Number
- NCT03635619
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, China
Cytoplasmic Activated PD-1 CAR T Cells in Refractory/Relapsed B Cell Lymphoma
Phase 1
- Conditions
- Relapsed Non Hodgkin Lymphoma
- Interventions
- First Posted Date
- 2018-05-30
- Last Posted Date
- 2018-05-30
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 15
- Registration Number
- NCT03540303
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
The Real World Study of Apatinib for Gastric Cancer Treatment in Henan Province
- Conditions
- Gastric Cancer
- First Posted Date
- 2018-03-27
- Last Posted Date
- 2020-05-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 1000
- Registration Number
- NCT03478943
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
S-1 Plus Gefitinib Versus Gefitinib Monotherapy in Patients With EGFR-sensitive Mutation Advanced Non-squamous NSCLC
Phase 2
- Conditions
- Advanced NSCLC With EGFR Mutation
- Interventions
- First Posted Date
- 2018-03-07
- Last Posted Date
- 2020-07-10
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT03457337
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
The FLOT Regimen Conversion Therapy of Adenocarcinoma of the Stomach / Gastroesophageal
Phase 2
- Conditions
- Adenocarcinoma of the Stomach / Gastroesophageal
- Interventions
- Drug: FLOT regimen chemotherapyProcedure: D2 gastric and imaging metastases resection
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2018-03-02
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 112
- Registration Number
- NCT03451942
- Locations
- π¨π³
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
A Retrospective Clinical Study of Apatinib in Combination With Radiotherapy / Chemotherapy Second-line and Above in the Treatment of Recurrent / Metastatic Head and Neck Squamous Cell Carcinoma
Phase 2
- Conditions
- Head and Neck Squamous Cell Carcinoma
- Interventions
- First Posted Date
- 2018-02-06
- Last Posted Date
- 2018-02-06
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 60
- Registration Number
- NCT03424291
- Locations
- π¨π³
Henan Cancer Hospital, Zhengzhou, Henan, China
An Observational Study to Evaluate Lymph Metastases and Prognoses of the Patients With Esophageal Cancer
- Conditions
- Esophageal Cancer
- Interventions
- Procedure: Surgeries
- First Posted Date
- 2018-01-30
- Last Posted Date
- 2018-01-30
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 3673
- Registration Number
- NCT03415815
- Locations
- π¨π³
China-Japan Friendship Hospital, Beijing, Beijing, China
π¨π³China PLA General Hospital, Beijing, Beijing, China
π¨π³Henan cancer hospital, Zhengzhou, Henan, China
Lobaplation or Cisplatin in Adjuvant Chemotherapy for Esophageal Carcinoma
- First Posted Date
- 2018-01-29
- Last Posted Date
- 2020-08-28
- Lead Sponsor
- Henan Cancer Hospital
- Target Recruit Count
- 733
- Registration Number
- NCT03413436
- Locations
- π¨π³
Henan Cancer Hospital/The affiliated Cancer Hospital of ZhengZhou university, ZhengZhou, Henan, China
Β© Copyright 2025. All Rights Reserved by MedPath